Alzheimer’s drug shows promise in early results of study

Sep 27, 2022, 6:06 PM | Updated: Sep 28, 2022, 3:00 pm
FILE — The Biogen Inc., headquarters is shown March 11, 2020, in Cambridge, Mass.  Shares of Biog...

FILE — The Biogen Inc., headquarters is shown March 11, 2020, in Cambridge, Mass. Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday, Sept. 28, 2022, after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease’s progress in a late-stage study. Eisai announced results late Tuesday from a global study of nearly 1,800 people with early-stage Alzheimer’s (AP Photo/Steven Senne, File)

(AP Photo/Steven Senne, File)

Shares of Biogen and other drugmakers researching Alzheimer’s disease soared Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study.

The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment.

Eisai announced results late Tuesday from a global study of nearly 1,800 people with early-stage Alzheimer’s.

Patients were monitored using a scale that measures mental decline and their ability to do daily activities like getting dressed or feeding oneself.

Eisai Co. Ltd. said it would discuss full results from the research at a conference in late November. It also plans to publish findings in a peer-reviewed medical journal.

The company is already seeking an accelerated approval from the U.S. Food and Drug Administration, and the agency is expected to decide by early next year. Eisai and Biogen will co-promote the drug.

Researchers typically urge caution in evaluating a study until the full results are released. But the initial findings appear to be “quite robust” and will likely support regulatory approval, Mizuho Securities analyst Graig Suvannavejh said in a research note.

A statement from the Alzheimer’s Association called the findings the most encouraging to date for potential treatments of the underlying disease causes.

Some 6 million people in the U.S. and many more worldwide have Alzheimer’s, which gradually attacks areas of the brain needed for memory, reasoning, communication and basic daily tasks.

Alzheimer’s has no known cure. Long-standing treatments on the market just manage symptoms, and researchers don’t fully understand what causes the disease.

Last year, Biogen’s Aduhelm became the first new Alzheimer’s drug introduced in nearly two decades. But it has largely flopped after debuting with a price tag of $56,000 annually, which Biogen later slashed.

Doctors have been hesitant to prescribe it, given weak evidence that the drug slows the progression of Alzheimer’s. Insurers have blocked or restricted coverage due to concerns over the drug’s high price tag and uncertain benefit.

Earlier this year, the federal Medicare program imposed strict limits on who can get the drug, wiping out most of its potential U.S. market. Biogen announced afterward that it would stop most of its spending on the treatment.

Like Aduhelm, lecanemab, which Eisai developed, aims to clear a protein called beta-amyloid from the brain.

The protein forms a plaque that researchers believe is a contributor to Alzheimer’s. They also point to other potential factors like family history and chronic conditions such as diabetes.

Eisai executives say lecanemab focuses more on floating clumps of the protein before it forms the plaque, which is what Aduhelm targets.

Eli Lilly and Co. also is developing a potential treatment, donanemab, that targets the protein.

Shares of Cambridge, Massachusetts-based Biogen Inc. jumped 40% to close Wednesday at $276.61. The stock had largely tumbled since Aduhelm’s debut last year.

Shares of Indianapolis-based Eli Lilly and Co. rose 7.5%.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

AP

murders...
Associated Press

Appeals court upholds most Eyman campaign finance violations

A Washington state Court of Appeals on Tuesday upheld most of the campaign finance violations that longtime anti-tax initiative promoter Tim Eyman was found liable for last year.
18 hours ago
A Washington State Department of Agriculture worker displays an Asian giant hornet taken from a nes...
Associated Press

No northern giant hornets found in 2022 in Washington state

Citizen trapping of northern giant hornets in northwest Washington ended Nov. 30 without any confirmed sightings of the hornets this year, state officials said Tuesday.
18 hours ago
Associated Press

Deep, 5.8 magnitude quake shakes Indonesia’s capital

JAKARTA, Indonesia (AP) — A strong and deep earthquake shook Indonesia’s capital and other parts of the main island Java on Thursday but there were no immediate reports of serious damage or casualties. High-rises in Jakarta, the capital, swayed for several seconds and some ordered evacuations. The U.S. Geological Survey said the 5.8 magnitude earthquake […]
18 hours ago
FILE - Military personnel watch as Air Force One, with President Donald Trump, aboard prepares to d...
Associated Press

Boeing’s last 747 to roll out of Washington state factory

SEATTLE (AP) — After more than half a century, the last Boeing 747 rolled out of a Washington state factory on Tuesday. The 747 jumbo jet has taken on numerous roles — a cargo plane, a commercial aircraft capable of carrying nearly 500 passengers, and the Air Force One presidential aircraft — since it debuted […]
18 hours ago
FILE - Jailed, former Guatemalan President Otto Perez Molina attends his pre-trial hearing for alle...
Associated Press

Guatemalan court convicts ex-president of fraud, conspiracy

GUATEMALA CITY (AP) — A court in Guatemala convicted former President Otto Pérez Molina and his vice president, Roxana Baldetti, on fraud and conspiracy counts Wednesday. Their sentences have yet to be announced. Both were acquitted of illegal enrichment charges. Pérez Molina and Baldetti resigned in 2015 and have been in custody on charges of […]
18 hours ago
Hywind Scotland, the world's first commercial wind farm using floating wind turbines, is visible of...
Associated Press

1st US floating offshore wind auction nets $757M in bids

PORTLAND, Ore. (AP) — The first-ever U.S. auction of leases to develop commercial-scale floating wind farms in the deep waters off the West Coast attracted $757 million in winning bids Wednesday from mostly European companies, in a project watched by other regions and countries just getting their own plans for floating offshore wind started. The […]
18 hours ago

Sponsored Articles

Comcast Ready for Business Fund...
Ilona Lohrey | President and CEO, GSBA

GSBA is closing the disparity gap with Ready for Business Fund

GSBA, Comcast, and other partners are working to address disparities in access to financial resources with the Ready for Business fund.
SHIBA WA...

Medicare open enrollment is here and SHIBA can help!

The SHIBA program – part of the Office of the Insurance Commissioner – is ready to help with your Medicare open enrollment decisions.
Lake Washington Windows...

Choosing Best Windows for Your Home

Lake Washington Windows and Doors is a local window dealer offering the exclusive Leak Armor installation.
Anacortes Christmas Tree...

Come one, come all! Food, Drink, and Coastal Christmas – Anacortes has it all!

Come celebrate Anacortes’ 11th annual Bier on the Pier! Bier on the Pier takes place on October 7th and 8th and features local ciders, food trucks and live music - not to mention the beautiful views of the Guemes Channel and backdrop of downtown Anacortes.
Swedish Cyberknife Treatment...

The revolutionary treatment of Swedish CyberKnife provides better quality of life for majority of patients

There are a wide variety of treatments options available for men with prostate cancer. One of the most technologically advanced treatment options in the Pacific Northwest is Stereotactic Body Radiation Therapy using the CyberKnife platform at Swedish Medical Center.
Work at Zum Services...

Seattle Public Schools announces three-year contract with Zum

Seattle Public Schools just announced a three-year contract with a brand-new company to the Pacific Northwest to assist with their student transportation: Zum.
Alzheimer’s drug shows promise in early results of study